Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare Technologies (Nasdaq: GEHC) has announced its quarterly dividend payment. The company's Board of Directors has declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025. The dividend will be paid on August 15, 2025 to shareholders of record as of July 25, 2025.

GE HealthCare (NASDAQ: GEHC) has received FDA approval for expanded indications of its Vizamyl PET imaging agent for beta-amyloid detection. The updated label now includes quantification capabilities for more objective amyloid measurements in the brain and removes previous limitations.

Key updates include the ability to monitor patient response to anti-amyloid therapies, predict development of dementia due to Alzheimer's disease, select patients for anti-amyloid therapies, and establish Alzheimer's disease diagnosis. The quantification feature enables calculation of amyloid load, improving diagnostic confidence and consistency among readers.

GE HealthCare showcases its advanced molecular imaging solutions at SNMMI 2025, highlighting its commitment to cardiac diagnostics. The company's flagship product, Flyrcado (flurpiridaz F 18) injection, represents a major breakthrough in nuclear cardiology as the first new PET myocardial perfusion tracer in nearly 20 years. The solution offers higher diagnostic efficacy compared to traditional SPECT MPI for coronary artery disease detection. Notably, Flyrcado has achieved significant coverage milestones, including CMS pass-through status and coverage by all Medicare Administrative Contractors, with over 50% of commercially insured beneficiaries now covered. GE HealthCare's portfolio also includes the Omni Legend PET/CT system, which has become their fastest-selling PET/CT platform, along with StarGuide and Aurora SPECT/CT systems for comprehensive cardiac imaging.

GE HealthCare (GEHC) unveils innovative advancements in theranostics and molecular imaging at SNMMI 2025, headlined by the introduction of LesionID Pro with automated zero-click pre-processing. This AI-powered software aims to streamline tumor analysis by eliminating manual segmentation requirements. The company showcases a comprehensive portfolio including the MINItrace Magni cyclotron, Omni Legend PET/CT system (reducing dose by up to 40%), StarGuide digital SPECT/CT, Aurora dual-head SPECT/CT, and Theranostics Pathway Manager Tile. These solutions support the growing field of theranostics, which combines diagnostic imaging and targeted therapies for personalized cancer treatment. The technology suite addresses the critical need for precision care solutions in oncology, where cancer causes over 10 million deaths globally each year.

GE HealthCare (GEHC) has renewed its research collaboration with Stanford Medicine to advance total body PET/CT technology, aiming to enhance clinical care and patient outcomes. The partnership focuses on developing next-generation imaging solutions that offer ultra-high sensitivity, reduced scan times, and improved diagnostic capabilities. The technology is designed to support personalized medicine practices, particularly in oncology, pediatric imaging, and theranostics. Key features include ultra-low dose scans, fast acquisitions, multi-organ dynamic imaging, and dual tracer imaging. Stanford Medicine experts highlight the technology's potential to revolutionize molecular imaging studies, reduce anesthesia use in pediatric cases, and improve healthcare system efficiency. This collaboration builds on GE HealthCare's history of innovation in medical imaging, including their development of the first commercially available PET/CT solution.

GE HealthCare announces its first combined software release with MIM Encore, integrating GE HealthCare's proprietary features with MIM Software's technology to enhance digital imaging and workflow solutions. The integrated platform offers advanced capabilities across oncology, cardiology, and neurology departments, featuring automated read preparation, structured reporting, and flexible interpretation tools for PET/CT and SPECT/CT imaging. Following GE HealthCare's acquisition of MIM Software in 2024, MIM Encore delivers streamlined workflows, resolution recovery, and image-enhancing tools specifically tailored for GE HealthCare scanners. The solution aims to improve operational efficiency, enhance diagnostic confidence, and support personalized medicine through advanced quantitation tools and automated processes.

PharmaLogic Holdings Corp. has appointed Etienne Montagut as its new President and Chief Executive Officer, effective June 1, 2025. Montagut, who previously served as President, brings over 25 years of senior leadership experience in the pharmaceutical industry, with previous executive roles at Lantheus, GE HealthCare, and Ipsen. He succeeds Steve Chilinski, who retired after leading the company through 13 years of growth and will transition to Executive Chairman of the Board. The leadership change positions PharmaLogic, a leading radiopharmaceutical CDMO, to continue its expansion in novel diagnostics and therapies development.

GE HealthCare (GEHC) announced that NCCN Guidelines now recommend fluoroestradiol (FES) PET imaging for systemic staging in patients with recurrent or metastatic lobular breast cancer. The company's Cerianna (fluoroestradiol F18) injection is the only FDA-approved imaging agent for detecting estrogen receptor positive (ER+) breast cancer metastases. This update expands the 2023 guidelines that included FES PET for systemic staging of recurrent/stage IV ER+ breast cancer. Invasive lobular cancer (ILC) represents 10-15% of all breast cases, with approximately 43,000 new cases annually, and 95% of ILC tumors are ER+. The guidelines' update could improve diagnostic accuracy, facilitate earlier interventions, enhance clinical decision-making, and potentially lead to broader insurance coverage for breast cancer patients.

GE HealthCare (GEHC) has launched CleaRecon DL, an AI-powered technology that enhances cone-beam computed tomography (CBCT) image quality in interventional procedures. The solution, which received both FDA 510(k) clearance and CE mark, uses deep-learning algorithms to eliminate streak artifacts caused by blood flow pulsatility during liver, prostate, neuro, and endovascular procedures.

Clinical validation testing demonstrated impressive results, with 98% of cases showing clearer images compared to conventional CBCT, and 94% improvement in image interpretation confidence. The technology will be available on the Allia™ platform in the United States and European Union, addressing traditional CBCT limitations that have historically hindered image clarity and clinical adoption.